Molecular blocking of CD23 supports its role in the pathogenesis of arthritis.
BACKGROUND
CD23 is a differentiation/activation antigen expressed by a variety of hematopoietic and epithelial cells. It can also be detected in soluble forms in biological fluids. Initially known as the low-affinity receptor for immunoglobulin E (Fc epsilonRII), CD23 displays various other physiologic ligands such as CD21, CD11b/c, CD47-vitronectin, and mannose-containing proteins. CD23 mediates numerous immune responses by enhancing IgE-specific antigen presentation, regulating IgE synthesis, influencing cell differentiation and growth of both B- and T-cells. CD23-crosslinking promotes the secretion of pro-inflammatory mediators from human monocytes/macrophages, eosinophils and epithelial cells. Increased CD23 expression is found in patients during allergic reactions and rheumatoid arthritis while its physiopathologic role in these diseases remains to be clarified.


RESULTS
We previously generated heptapeptidic countrestructures of human CD23. Based on in vitro studies on healthy and arthritic patients' cells, we showed that CD23-specific peptide addition to human macrophages greatly diminished the transcription of genes encoding inflammatory cytokines. This was also confirmed by significant reduction of mediator levels in cell supernatants. We also show that CD23 peptide decreased IgE-mediated activation of both human and rat CD23(+) macrophages. In vivo studies in rat model of arthritis showed that CD23-blocking peptide ameliorates clinical scores and prevent bone destruction in a dose dependent manner. Ex-vivo analysis of rat macrophages further confirmed the inhibitory effect of peptides on their activation. Taken together our results support the role of CD23 activation and subsequent inflammatory response in arthritis.


CONCLUSIONS
CD23-blocking peptide (p30A) prevents the activation of monocytes/macrophages without cell toxicity. Thus, targeting CD23 by antagonistic peptide decreases inflammatory markers and may have clinical value in the treatment of human arthritis and allergic reactions involving CD23.
Rambert
Jérôme
J
Groupe Thérapeutiques d'inflammation et d'infection, Laboratoire d'Immunologie et de Parasitologie, UFR Sciences Pharmaceutiques, Université Bordeaux 2, Bordeaux, France.
Mamani-Matsuda
Maria
M
Moynet
Daniel
D
Dubus
Pierre
P
Desplat
Vanessa
V
Kauss
Tina
T
Dehais
Joël
J
Schaeverbeke
Thierry
T
Ezzedine
Khaled
K
Malvy
Denis
D
Vincendeau
Philippe
P
Mossalayi
M Djavad
MD
D000818:Animals; D001168:Arthritis / Q000276:immunology*; D001483:Base Sequence; D015153:Blotting, Western; D016022:Case-Control Studies; D017931:DNA Primers; D005260:Female; D006801:Humans; D017737:Macrophages, Peritoneal / Q000276:immunology; D051381:Rats; D011917:Rats, Inbred Lew; D017455:Receptors, IgE / Q000037:antagonists & inhibitors* / Q000502:physiology; D015398:Signal Transduction
D017931:DNA Primers; D017455:Receptors, IgE